Key Highlights
- Matthew Kowalsky appointed as Chief Legal Officer of Enanta Pharmaceuticals, leading legal and compliance initiatives.
- Brings over 20 years of legal expertise in the life sciences sector, with roles at Sigilon Therapeutics and Proteon Therapeutics.
- Kowalsky’s arrival coincides with Enanta’s progress on drug developments for virology and immunology.
Source: Business Wire
Notable Quotes
- “I’m proud to join a team with an established track record of success, dedicated to the discovery and development of groundbreaking small molecule drugs in areas of significant unmet medical need,” – Matthew Kowalsky, Chief Legal Officer at Enanta Pharmaceuticals
- “Matt’s broad legal expertise…makes him an important addition to the Enanta leadership team as we advance toward several important catalysts this year,” – Jay R. Luly, Ph.D., President and CEO at Enanta Pharmaceuticals
SoHC's Take
The appointment of Matthew Kowalsky as Chief Legal Officer at Enanta Pharmaceuticals underscores a strategic enhancement in leadership that is pivotal for navigating the complex legal landscapes of biotechnology. His extensive experience across various legal roles within the life sciences industry equips him uniquely to spearhead Enanta’s ongoing legal and compliance operations effectively. This move is timely as Enanta gears up for crucial phases in its drug development projects, aiming to make significant impacts in virology and immunology. Kowalsky’s leadership is expected to be a key asset in driving forward Enanta’s mission to develop essential medicines and in managing the intricate regulatory and legal challenges that come with biotech innovations.
